U. IŞIK Et Al. , "Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.," ASCO 2019 , vol.37, Chicago, United States Of America, pp.16075, 2019
IŞIK, U. Et Al. 2019. Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.. ASCO 2019 , (Chicago, United States Of America), 16075.
IŞIK, U., KÖSTEK, O., DEMİRAY, A. G., DİRİCAN, A., ŞİMŞEK, M., BÜYÜKŞİMŞEK, M., ... UÇAR, G.(2019). Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer. . ASCO 2019 (pp.16075). Chicago, United States Of America
IŞIK, ULAŞ Et Al. "Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.," ASCO 2019, Chicago, United States Of America, 2019
IŞIK, ULAŞ Et Al. "Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.." ASCO 2019 , Chicago, United States Of America, pp.16075, 2019
IŞIK, U. Et Al. (2019) . "Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.." ASCO 2019 , Chicago, United States Of America, p.16075.
@conferencepaper{conferencepaper, author={ULAŞ IŞIK Et Al. }, title={Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.}, congress name={ASCO 2019}, city={Chicago}, country={United States Of America}, year={2019}, pages={16075} }